Amid growing frustration over the cost and development of tuberculosis medicines, the U.S. government is pushing changes in global policy at a United Nations meeting this week that patient advocacy groups claim will make access and affordability more difficult for poorer countries.

Specifically, the U.S. has proposed language that would negate provisions found in a World Trade Organization agreement, which allows countries to issue compulsory licenses as a way to create lower-cost alternatives to medicines, according to the latest draft version of an agreement.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy